$159.82▾ 1.04%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.27cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
6th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
+39.5%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 17% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Neurocrine Biosciences, Inc. turns 127¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year. Its valuation sits in the cheaper end of its own recent range.
Key numbers
Valuation
EPS (TTM)$6.82
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin20.9%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$3.37B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.